If disruption of B cell differentiation and its impact on subsequent processes in RA are the mechanism by which BTK inhibitors demonstrate efficacy, this may ultimately prove to be a patient selection criteria in precision medicine for determining appropriate therapy in RA. The gene discussed is BTK; the disease is rheumatoid arthritis.